Pilocytic astrocytoma: a disease with evolving molecular heterogeneity (Q28286218)

https://api.crossref.org/works/10.1177%2F0883073813476141

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Predictive factors for early symptomatic recurrence in pilocytic astrocytoma: does angiogenesis have a role to play?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Intracranial gliomas in neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Natural history and management of low-grade glioma in NF-1 children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Anaplasia in pilocytic astrocytoma predicts aggressive behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073813476141

release_4qgpov3vi5g2hmeykefbcjsa2a

21 January 2018

Identifiers

DOI

10.1177/0883073813476141

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4qgpov3vi5g2hmeykefbcjsa2a